$CRSP
CRISPR Therapeutics AG

2024 Q2 Form 10-Q Financial Statement

#000095017024055719 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $517.0K $504.0K $100.0M
YoY Change -99.26% -99.5% 10538.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $71.61M $64.92M $64.55M
YoY Change 12.48% 0.57% 10.03%
% of Gross Profit
Research & Development $80.17M $76.17M $99.94M
YoY Change -21.06% -23.78% -15.48%
% of Gross Profit
Depreciation & Amortization $4.800M $4.833M $5.051M
YoY Change -3.25% -4.32% -16.36%
% of Gross Profit
Operating Expenses $151.8M $141.1M $164.5M
YoY Change -8.14% -14.22% -7.02%
Operating Profit -$151.3M -$140.6M -$64.49M
YoY Change 58.85% 118.01% -63.35%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $26.14M $24.72M $12.74M
YoY Change 42.01% 94.0% 3410.19%
Pretax Income -$125.1M -$115.9M -$51.75M
YoY Change 62.88% 123.92% -70.53%
Income Tax $1.300M $700.0K $1.300M
% Of Pretax Income
Net Earnings -$126.4M -$116.6M -$53.07M
YoY Change 62.6% 119.71% -70.39%
Net Earnings / Revenue -24450.29% -23133.13% -53.07%
Basic Earnings Per Share -$1.49 -$1.43 -$0.67
Diluted Earnings Per Share -$1.49 -$1.43 -$0.67
COMMON SHARES
Basic Shares Outstanding 84.92M 80.28M 78.65M
Diluted Shares Outstanding 84.92M 81.79M 78.68M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $672.5M $1.162B $608.0M
YoY Change -61.97% 91.19% -26.1%
Cash & Equivalents $484.5M $707.4M $344.4M
Short-Term Investments $188.0M $455.0M $263.6M
Other Short-Term Assets $8.788M $11.50M $24.80M
YoY Change -59.07% -53.63% -36.76%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.010B $2.120B $1.908B
YoY Change 8.11% 11.09% -15.6%
LONG-TERM ASSETS
Property, Plant & Equipment $143.0M $147.3M $162.2M
YoY Change -55.1% -9.21% 3.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $11.22M $0.00 $6.320M
YoY Change 128.85% -100.0%
Other Assets $15.14M $9.368M $2.760M
YoY Change 8.35% 239.42% -36.26%
Total Long-Term Assets $329.4M $319.4M $336.4M
YoY Change -2.37% -5.06% -2.65%
TOTAL ASSETS
Total Short-Term Assets $2.010B $2.120B $1.908B
Total Long-Term Assets $329.4M $319.4M $336.4M
Total Assets $2.340B $2.439B $2.244B
YoY Change 6.5% 8.67% -13.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.452M $16.46M $45.15M
YoY Change -65.74% -63.54% 66.55%
Accrued Expenses $91.88M $76.43M $85.63M
YoY Change -12.22% -10.74% 17.9%
Deferred Revenue $4.759M $4.072M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $127.8M $119.0M $146.8M
YoY Change -3.77% -18.94% 29.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.646M $3.615M $5.799M
YoY Change -98.53% -37.66% -20.94%
Total Long-Term Liabilities $3.646M $3.615M $5.799M
YoY Change -98.53% -37.66% -20.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $127.8M $119.0M $146.8M
Total Long-Term Liabilities $3.646M $3.615M $5.799M
Total Liabilities $358.9M $355.1M $389.5M
YoY Change -5.8% -8.83% 7.81%
SHAREHOLDERS EQUITY
Retained Earnings -$1.243B -$1.116B -$899.2M
YoY Change 27.21% 24.15% 139.69%
Common Stock $3.227B $3.202B $2.764B
YoY Change 15.16% 15.86% 4.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $62.00K $62.00K $63.00K
YoY Change -1.59% -1.59% 0.0%
Treasury Stock Shares $180.3K
Shareholders Equity $1.981B $2.084B $1.855B
YoY Change
Total Liabilities & Shareholders Equity $2.340B $2.439B $2.244B
YoY Change 6.5% 8.67% -13.88%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$126.4M -$116.6M -$53.07M
YoY Change 62.6% 119.71% -70.39%
Depreciation, Depletion And Amortization $4.800M $4.833M $5.051M
YoY Change -3.25% -4.32% -16.36%
Cash From Operating Activities -$95.58M $109.8M $8.799M
YoY Change -28.27% 1147.32% -106.51%
INVESTING ACTIVITIES
Capital Expenditures $707.0K $721.0K $3.059M
YoY Change -86.01% -76.43% -80.07%
Acquisitions
YoY Change
Other Investing Activities -$126.2M -$97.08M $120.9M
YoY Change -156.85% -180.3% -221.91%
Cash From Investing Activities -$126.9M -$97.80M $117.8M
YoY Change -158.5% -183.0% -202.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -466.0K 305.9M 5.404M
YoY Change -102.78% 5561.25% -49.25%
NET CHANGE
Cash From Operating Activities -95.58M 109.8M 8.799M
Cash From Investing Activities -126.9M -97.80M 117.8M
Cash From Financing Activities -466.0K 305.9M 5.404M
Net Change In Cash -223.0M 317.9M 132.1M
YoY Change -321.97% 140.7% -155.23%
FREE CASH FLOW
Cash From Operating Activities -$95.58M $109.8M $8.799M
Capital Expenditures $707.0K $721.0K $3.059M
Free Cash Flow -$96.29M $109.0M $5.740M
YoY Change -30.38% 1799.49% -103.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001674416
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37923
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
CY2024Q1 dei Entity Address Country
EntityAddressCountry
CH
CY2024Q1 dei City Area Code
CityAreaCode
41 (0)41
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
561 32 77
CY2024Q1 dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
CY2024Q1 dei Trading Symbol
TradingSymbol
CRSP
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
84918093
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
707427000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
389477000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1400698000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1304215000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
200000000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11499000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14386000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2119624000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1908078000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147253000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151945000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1973000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11516000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11591000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
151254000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153993000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9368000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1975000
CY2024Q1 us-gaap Assets
Assets
2439017000
CY2023Q4 us-gaap Assets
Assets
2229571000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
16463000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38147000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76432000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45335000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4072000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4105000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
1207000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
438000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15992000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15625000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4824000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5141000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
118990000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
108791000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13541000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14012000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
218935000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
223007000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3615000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
958000
CY2024Q1 us-gaap Liabilities
Liabilities
355081000
CY2023Q4 us-gaap Liabilities
Liabilities
346768000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130452265
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126536183
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85007926
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80214694
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84837610
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80044378
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2658000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2497000
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170316
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
170316
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
62000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81794630
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78676986
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1875479000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
62000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3199183000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2878155000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1116291000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-999700000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1552000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1913000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2083936000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1882803000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2439017000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2229571000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
504000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
100000000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
76172000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99935000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17953000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22360000
CY2024Q1 crsp Collaboration Expense
CollaborationExpense
46966000
CY2023Q1 crsp Collaboration Expense
CollaborationExpense
42192000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
141091000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
164487000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-140587000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-64487000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24720000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12742000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24720000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12742000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-115867000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51745000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
724000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1320000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-116591000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53065000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3454000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6227000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-120056000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46806000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81794630
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78676986
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
5000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4683000
CY2023Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20875000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6259000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53065000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1854896000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1882803000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
277147000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
7000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23866000
CY2024Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
764000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19405000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3465000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-116591000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2083936000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-116591000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-53065000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4833000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5051000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
19405000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20875000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
8385000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
969000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-200000000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2949000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12040000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9443000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25214000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-504000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2024Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-966000
CY2023Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-177000
CY2024Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-432000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-170000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
109752000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8799000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
721000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3059000
CY2024Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
7500000
CY2023Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
326915000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
265627000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
237336000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
386515000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97800000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
117829000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
280745000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2024Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
25189000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5404000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
305934000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5404000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
317875000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
132064000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
401068000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
224060000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
718943000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
356124000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
131000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2633000
CY2024Q1 crsp Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities
EquityIssuanceCostsInAccountsPayableAccruedExpensesAndOtherLongTermLiabilities
4522000
CY2023Q1 crsp Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities
EquityIssuanceCostsInAccountsPayableAccruedExpensesAndOtherLongTermLiabilities
155000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
707427000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344407000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11516000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11717000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
718943000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
356124000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
455000000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
197800000
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
252522000
CY2024Q1 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2024Q1 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
115000
CY2024Q1 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
252407000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1402153000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1383000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2838000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1400698000
CY2024Q1 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1654675000
CY2024Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
1383000
CY2024Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
2953000
CY2024Q1 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1653105000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
191721000
CY2023Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
0
CY2023Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
0
CY2023Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
191721000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1304304000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3821000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1937000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1306188000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1496025000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
3821000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
1937000
CY2023Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1497909000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1600000
CY2023Q4 crsp Debt Securities Available For Sale Unrealized Gain Position
DebtSecuritiesAvailableForSaleUnrealizedGainPosition
1900000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
893800000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
463500000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
125900000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
138400000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2024Q1 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
205505000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
205378000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58252000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
53433000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147253000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151945000
CY2024Q1 us-gaap Depreciation
Depreciation
4800000
CY2023Q1 us-gaap Depreciation
Depreciation
5000000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7480000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17347000
CY2024Q1 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
13502000
CY2023Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16962000
CY2024Q1 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
47767000
CY2023Q4 crsp Accrued Collaboration Costs
AccruedCollaborationCosts
2395000
CY2024Q1 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
2505000
CY2023Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
3143000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3348000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2515000
CY2024Q1 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1363000
CY2023Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1642000
CY2024Q1 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
34000
CY2023Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
630000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
433000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
701000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
76432000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45335000
CY2022 crsp Accounting Analysis Defer Option Specified Cost
AccountingAnalysisDeferOptionSpecifiedCost
110300000
CY2023 crsp Accounting Analysis Defer Option Specified Cost
AccountingAnalysisDeferOptionSpecifiedCost
110300000
CY2023 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
80900000
CY2022 crsp Deferred Finance Costs Share Lending Arrangement Issuance Costs
DeferredFinanceCostsShareLendingArrangementIssuanceCosts
36100000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2024Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
19925932
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
280000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
71.5
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
279000000
CY2024Q1 crsp Stamp Taxes Due On Issuance Of Common Stock
StampTaxesDueOnIssuanceOfCommonStock
2800000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19405000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20875000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7204372
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.05
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
811624
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
72.94
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
632683
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
38.72
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
218964
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
71.2
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7164349
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.03
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4471078
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
55.62
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7164349
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
58.03
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9255011
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9605924
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.026

Files In Submission

Name View Source Status
0000950170-24-055719-index-headers.html Edgar Link pending
0000950170-24-055719-index.html Edgar Link pending
0000950170-24-055719.txt Edgar Link pending
0000950170-24-055719-xbrl.zip Edgar Link pending
crsp-20240331.htm Edgar Link pending
crsp-20240331.xsd Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
crsp-20240331_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending